TargetCancer Foundation’s funded research in rare cancers has yielded groundbreaking discoveries published in numerous peer-reviewed journals. This consistent contribution to rare cancer knowledge underscores our commitment to expertise, authoritative research, and trustworthy information in the rare cancer community.
Featured Publication
“Living Guidelines for Tumor-Agnostic Therapies: A Pathway to Next-Generation Cancer Treatment” JCO Precision Oncology – Read Article
Living Guidelines for Tumor-Agnostic Therapies: A Pathway to Next-Generation Cancer Treatment
April 2026JCO Precision Oncology
Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
May 2025Cancer Discovery
Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras
April 2025American Society of Clinical Oncology Educational Book
FGFR Inhibition Blocks NF-ĸB-dependent Glucose Metabolism and Confers Metabolic Vulnerabilities in Cholangiocarcinoma
May 2024Nature Communications
Home-run trials for rare cancers: giving the right drug(s) to the right patients at the right time and in the right place
December 2023Precision Oncolology
SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers
March 2023Nature Cancer
EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion-positive cholangiocarcinoma
April 2022Cancer Discovery
Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma
March 2022Cancer Discovery
Biology of IDH mutant cholangiocarcinoma
February 2022Hepatology
FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma
October 2021Cancer Discovery
TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma
May 2019Cancer Discovery
Kras and Tp53 Mutations Cause Cholangiocyte- and Hepatocyte-Derived Cholangiocarcinoma
August 2018Cancer Research
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
May 2018Nature Medicine
New Horizons for Precision Medicine in Biliary Tract Cancers
September 2017Cancer Discovery
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma
December 2016Cancer Discovery
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
June 2016Cancer Discovery
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets
April 2016Oncotarget
Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma
January 2016Clinical Cancer Research
Biliary Tract Cancers: Finding Better Ways to Lump and Split
August 2015Journal of Clinical Oncology
Paired exome analysis of Barrett’s esophagus and adenocarcinoma
July 2015Nature Genetics
Epithelial PD-L2 expression marks Barrett’s Esophagus and Esophageal Adenocarcinoma
June 2015Cancer Immunology Research
YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression
March 2015Cell Reports
IDH mutations in liver cell plasticity and biliary cancer
November 2014Cell Cycle
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer
September 2014Nature
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice
March 2014Genes and Development